Annalisa Jenkins

Viventia Biotech, Inc. discovers, develops, manufactures, and commercializes monoclonal antibody products. Its products are used to treat head, neck, and bladder cancers. The company was founded by Albert D. Friesen in 1995 and is headquartered in Toronto, Canada

Biothera, Inc. develops natural gluco polysaccharide that engages and directs natural innate immune systems. The company was founded by Daniel Conners in 1997 and is headquartered in Eagan, MN.

Cocoon Biotech, Inc. develops and manufactures medicines for osteoarthritis patients. The company was founded by Ailis Tweed-Kent in 2013 and is headquartered in Cambridge, MA.

Vium, Inc. provides technology for preclinical drug discovery services. It offers biomedical investigators with technology that accelerates the preclinical drug discovery and development pipeline. The company was founded by Timothy L. Robertson and Jonathan Betts-Lacroix in 2013 and is headquartered in San Mateo, CA.

Merck Serono SA operates as a holding company in the pharmaceutical field. It engages in the research, development, manufacture, and distribution of therapeutic products for the treatment of human diseases. The company was founded on May 21, 1987 and is headquartered in Coinsins, Switzerland.

Part of Leadership Foundations, Women's Forum, Inc. is a non-profit community for women leaders of diverse achievement. The private company is based in New York, NY.

Prosensa Holding NV engages in the development of ribonucleic acid-modulating, or RNA-modulating, therapeutics for the treatment of genetic disorders. The company focuses on rare neuromuscular and neurodegenerative disorders, Duchenne muscular dystrophy, myotonic dystrophy and Huntington's disease. It has developed a portfolio of clinical and pre-clinical RNA-based drug candidates. Prosensa's current clinical portfolio is focused on the treatment of Duchenne Muscular Dystrophy. The company was founded in 2002 and is headquartered in Leiden, the Netherlands.

CellMedical SA operates medical diagnostic laboratories. The company is headquartered in Thessaloniki, Greece.

Women in Bio, Inc. is an organization that supports women in the life sciences industry. The non-profit company is based in Bethesda, MD and has subsidiaries in the United States. The organization has 13 chapters in the United States and is funded by sponsors and partners who are dedicated to supporting diversity and inclusion for women of all ages. Founded in 2002, it offers professional educational programs, peer-to-peer learning, mentoring, and networking opportunities for women at all career levels. Women in Bio was founded by Faith L. Charles and Cynthia Wong Hu.

Kuur Therapeutics provides clinical cellular therapeutics services. It develops, manufactures and markets personalized cellular immunotherapeutics for infectious disease and cancer. Cell Medica has developed proprietary production technology enabling GMP compliant manufacture of antigen-specific T cells. The company was founded by Gregg Sando in 2006 and is headquartered in London, the United Kingdom.

The King's Fund organizes healthcare conferences and other events. The company was founded in 1897 and is headquartered in London, the United Kingdom.

Oncimmune Ltd. provides clinical testing services for cancer detection. The firm develops early cancer detection tests for lung, breast, colorectal, prostate, stomach, pancreatic and ovarian cancers. The company was founded by John F. R. Robertson in 2003 and is headquartered in Nottingham, the United Kingdom.

Perspectum Ltd. provides technology solutions for diagnosing and staging liver disease. The company was founded by Rajarshi Banerjee, Stefan Karl Neubauer, Matthew David Robson, Alastair Cavanagh, James Hugh Charteris Mallinson and John Michael Brady on September 18, 2012 and is headquartered in Oxford, the United Kindgom.

Dimension Therapeutics, Inc. engages in the development of novel treatments for rare diseases. Its activities include discoveries and development of therapeutic products for people living with rare diseases associated wit the liver and caused by genetic mutations. The company was founded by Ben Auspitz in June 20, 2013 and is headquartered in Cambridge, MA.

Genomics England Ltd. runs and delivers 100,000 genomes project. Its flagship project sequences 100,000 genomes from NHS patients with a rare disease and their families, and patients with cancer. The company was founded by Jeremy Hunt on July 5, 2013 and is headquartered in London, the United Kingdom.

Transcelerate Biopharma, Inc. is a non-profit consortium that collaborates with pharmaceutical and biotechnology companies to improve the delivery of new medicines. The non-profit company is based in King of Prussia, PA. The organization's mission is to identify, prioritize, design, and facilitate implementation of solutions to drive the efficient, effective, and high-quality delivery of new medicines. Transcelerate has 20 member companies and 30+ initiatives focused on improving the patient and site experience, enhancing sponsor efficiencies and drug safety, and harmonizing processes and sharing information. The company was founded by Garry Arthur Neil, and Janice Chang has been the CEO of the company since 2014.

Coqual, formerly known as the Center for Talent Innovation, is a nonprofit think tank that helps leaders create diverse, equitable, and inclusive workplaces. The non-profit company is based in New York, NY, and was founded by Sylvia Ann Hewlett. The company focuses on conducting cutting-edge research and providing advisory services on various identities, including gender, race, ethnicity, disability, veteran status, and LGBTQ. Coqual was founded in 2004 and offers in-depth research, thought leadership, and data-driven solutions to address bias and barriers to inclusion for underrepresented populations in the workplace. Lanaya Irvin has been the CEO of the company since 2020.

PlaqueTec Ltd. develops a liquid biopsy system platform technology that provides unparalleled resolution of the biological processes that cause coronary artery disease. The firm’s Liquid Biopsy System addresses the underlying biomarker collection problems preventing advances in CAD research. The company was founded by Stephen Blatcher in 2000 and is headquartered in Cambridge, the United Kingdom.

Viventia Bio, Inc. operates as a biologics oncology company, which focuses on designing, engineering, and developing targeted protein therapeutics. The company was founded by Leslie Lewis Dan in October 2012 and is headquartered in Winnipeg, Canada.

Biothera Pharmaceutical, Inc. operates as a biotechnology company. It develops Imprime PGG, a novel dectin receptor agonist that reverses tumor-mediated immunosuppression while promoting antigen presentation to drive T cell activation. The company was founded in 1997 and is headquartered in Roseville, MN.

iOX Therapeutics Ltd. provides cancer therapeutics services. The company was founded by Vincenzo Cerundolo in February 2015 and is headquartered in London, the United Kingdom.

AgeX Therapeutics, Inc. operates as a biotechnology company, which engages in the development and commercialization of novel therapeutics targeting human aging and degenerative diseases. Its product pipeline includes AGEX-VASC1, AGEX-BAT1, and AGEX-iTR1547. The company was founded by Michael D. West in 2017 and is headquartered in Alameda, CA.

Thrombolytic Science International LLC operates as a vascular medicine and biotech company. The company was founded by Alexis Wallace and Victor Gurewich and is headquartered in Cambridge, MA.

PhESi LLC provides drug and clinical development services for life sciences companies. The private company is based in East Lyme.

AOBiome Therapeutics, Inc. develops microbiome-targeted therapies for local, nasal and systemic inflammatory conditions. Its portfolio includes three clinical-stage programs, a Phase 2b study to treat patients with acne vulgaris, a Phase 2 trial to reduce elevated blood pressure, and a Phase 1b/2a clinical trial in allergic rhinitis, as well as earlier-stage preclinical programs targeting diverse inflammatory indications. The company was founded by Jamie Heywood, David Whitlock and Lenny Barshack in 2013 and is headquartered in Cambridge, MA.

Part of Affimed NV, Affimed GmbH is a clinical leader in innate immuno-oncology. The private company, based in Heidelberg, Germany, develops proprietary cancer-targeting bispecific antibodies that activate the innate immune system to kill tumor cells. Affimed leads clinical development of innate cell engagers for solid/hematologic tumors as monotherapy, in combination with NK cells or with checkpoint inhibitors. Adolf Hoess has been the CEO of the German company since 2010.

Part of Compass Pathways Plc, COMPASS Pathfinder Holdings Ltd. is an investment holding British company. The private company is based in London, UK and was founded in 2017.

Noxsudor Therapeutics Ltd. manufactures capsules that control sweating.

RYSE Asset Management LLP (RYSE) is a venture capital firm founded in 2010 by Atique Mirza. The firm is headquartered in London, the United Kingdom.

The Conduit Connect Ltd. is a private membership platform for high net worth, sophisticated, and professional impact investors. The company is based in London, UK. The British company connects founders who are building scalable, for-profit, impact-driven businesses to capital and expert resources. The company source and connects the most promising high growth impact investing opportunities to mission-aligned investors. The company was founded in 2018, and the CEO is Eva-Maria Dimitriadis.

Perspectum Group Plc engages in the sale of diagnostic products via a software-as-a-medical device platform. Its products combine expertise in image formation, magnetic resonance image analysis and artificial intelligence to support healthcare provider diagnosis, treatment decision-making, and monitoring of the progression of chronic metabolic diseases, multi-organ pathologies and cancer, and determine whether the patient is responding to therapy. Its products include Liver MultiScan, MRCP+, Hepatica, and CoverScan MD. The company was founded by Matthew Robson on June 10, 2021 and is headquartered in Oxford, the United Kingdom.